Identification of Novel Biomarkers for Predicting Kidney Injury Due to Drugs Using “Omic” Strategies

References

• Group K. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Kidney Int. 2012;2:1–138.
   Web of Science ®Google Scholar
• Hoste EAJ, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Medicine. 2015;41(8):1411–1423. doi:10.1007/s00134-015-3934-726162677
   PubMed Web of Science ®Google Scholar
• Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004;66(4):1613–1621. doi:10.1111/j.1523-1755.2004.00927.x15458458
   PubMed Web of Science ®Google Scholar
• Meyboom RHB, Egberts ACG, Edwards IR, Hekster YA, de Koning FHP, Gribnau FWJ. Principles of signal detection in pharmacovigilance. Drug Saf. 1997;16(6):355–365. doi:10.2165/00002018-199716060-000029241490
   PubMed Web of Science ®Google Scholar
• Mehta RL, Awdishu L, Davenport A, et al. Phenotype standardization for drug-induced kidney disease. Kidney Int. 2015;88(2):226–234. doi:10.1038/ki.2015.11525853333
   PubMed Web of Science ®Google Scholar
• Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129–1136. doi:10.1056/NEJMoa070733018337603
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–647.27282937
   PubMed Web of Science ®Google Scholar
• Perazella MA. Checkmate: kidney injury associated with targeted cancer immunotherapy. Kidney Int. 2016;90(3):474–476. doi:10.1016/j.kint.2016.05.02427521108
   PubMed Web of Science ®Google Scholar
• Jaimes EA. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma. Semin Nephrol. 2020;40(1):49–58.32130966
   PubMed Web of Science ®Google Scholar
• Lefebvre J, Glezerman IG. Kidney Toxicities Associated With Novel Cancer Therapies. Adv Chronic Kidney Dis. 2017;24(4):233–240. doi:10.1053/j.ackd.2017.05.00628778363
   PubMed Web of Science ®Google Scholar
• Malyszko J, Kozlowska K, Kozlowski L. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant. 2017;32(6):924–936.28339935
   PubMed Web of Science ®Google Scholar
• Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer. 2017;41(2):100–110. doi:10.1016/j.currproblcancer.2016.12.00428189263
   PubMed Web of Science ®Google Scholar
• Nussbaum EZ, Perazella MA. Update on the nephrotoxicity of novel anticancer agents. Clin Nephrol. 2018;89(3):149–165. doi:10.5414/CN10937129350175
   PubMed Web of Science ®Google Scholar
• Wanchoo R, Abudayyeh A, Doshi M, et al. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clin J Am Soc Nephrol. 2017;12(1):176–189. doi:10.2215/CJN.0610061627654928
   PubMed Web of Science ®Google Scholar
• Lu H, Han Y-J, Xu J-D, Xing W-M, Chen J, Zhang C. Proteomic characterization of acyclovir-induced nephrotoxicity in a mouse model. PLoS One. 2014;9(7):e103185. doi:10.1371/journal.pone.010318525055032
   PubMed Web of Science ®Google Scholar
• Rocha PN, Macedo MN, Kobayashi CD, et al. Role of urine neutrophil gelatinase-associated lipocalin in the early diagnosis of amphotericin B-induced acute kidney injury. Antimicrob Agents Chemother. 2015;59(11):6913–6921. doi:10.1128/AAC.01079-1526303800
   PubMed Web of Science ®Google Scholar
• Perez JD, Colucci JA, Sakata MM, Cunha TS, Arita DY, Casarini DE. Proteomic approaches in understanding a detected relationship between chemotherapy-induced nephrotoxicity and cell respiration in HK-2 cells. Nephron Physiol. 2011;119(1):pp1–10. doi:10.1159/000327575
   Google Scholar
• Wilmes A, Bielow C, Ranninger C, et al. Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol in Vitro. 2015;30(1):117–127. doi:10.1016/j.tiv.2014.10.00625450742
   PubMed Web of Science ®Google Scholar
• Montoro-Molina S, Quesada A, Zafra-Ruiz PV, et al. Immunological detection of glutamyl aminopeptidase in urine samples from cisplatin-treated rats. Proteomics Clin Appl. 2015;9(5–6):630–635. doi:10.1002/prca.20140009625470983
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang L, Chen Y-X, et al. Identification of nestin as a urinary biomarker for acute kidney injury. Am J Nephrol. 2014;39(2):110–121. doi:10.1159/00035826024503548
   PubMed Web of Science ®Google Scholar
• Bulacio RP, Torres AM. Organic anion transporter 5 (Oat5) renal expression and urinary excretion in rats treated with cisplatin: a potential biomarker of cisplatin-induced nephrotoxicity. Arch Toxicol. 2013;87(11):1953–1962. doi:10.1007/s00204-013-1062-023649842
   PubMed Web of Science ®Google Scholar
• Furukawa K, Yamane M, Tatsukawa H, Hitomi K. Early response as shown by enhancement of transglutaminase 1 expression after cisplatin-induced acute kidney injury. Arch Biochem Biophys. 2015;586(586):27–32. doi:10.1016/j.abb.2015.09.02126427353
   PubMed Web of Science ®Google Scholar
• George B, Wen X, Mercke N, et al. Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: time-dependent Changes in the Absence of Clinical Nephrotoxicity. Clin Pharmacol Ther. 2017;101(4):510–518. doi:10.1002/cpt.60628002630
   PubMed Web of Science ®Google Scholar
• George B, Wen X, Mercke N, et al. Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin chemotherapy. Toxicol Rep. 2020;7:571–576. doi:10.1016/j.toxrep.2020.04.00332382514
   PubMed Web of Science ®Google Scholar
• Lamoureux F, Gastinel LN, Mestre E, Marquet P, Essig M. Mapping cyclosporine-induced changes in protein secretion by renal cells using stable isotope labeling with amino acids in cell culture (SILAC). J Proteomics. 2012;75(12):3674–3687. doi:10.1016/j.jprot.2012.04.02422564819
   PubMed Web of Science ®Google Scholar
• Klawitter J, Klawitter J, Kushner E, et al. Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J Proteome Res. 2010;9(2):865–875. doi:10.1021/pr900761m19994912
   PubMed Web of Science ®Google Scholar
• Klawitter J, Klawitter J, Schmitz V, et al. Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism. J Proteome Res. 2012;11(11):5135–5144. doi:10.1021/pr300260e23057591
   PubMed Web of Science ®Google Scholar
• Betton GR, Kenne K, Somers R, Marr A, Dixit R. Protein biomarkers of nephrotoxicity; a review and findings with cyclosporin A, a signal transduction kinase inhibitor and N-phenylanthranilic acid. Cancer Biomarkers. 2005;1(1):59–67. doi:10.3233/CBM-2005-110717192032
   PubMedGoogle Scholar
• Shu Z, Pu X, Xiong X, Li Q, Wang Y, Zhai S. Differential expression of plasma proteins in cyclosporine A-induced rat acute nephrotoxicity. Biosci Biotechnol Biochem. 2009;73(3):592–598. doi:10.1271/bbb.8067719270397
   PubMed Web of Science ®Google Scholar
• Ferreira L, Quiros Y, Sancho-Martinez SM, et al. Urinary levels of regenerating islet-derived protein III β and gelsolin differentiate gentamicin from cisplatin-induced acute kidney injury in rats. Kidney Int. 2011;79(5):518–528. doi:10.1038/ki.2010.43920980976
   PubMed Web of Science ®Google Scholar
• Rouse R, Siwy J, Mullen W, Mischak H, Metzger J, Hanig J. Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat. PLoS One. 2012;7(4):e34606. doi:10.1371/journal.pone.003460622509332
   PubMed Web of Science ®Google Scholar
• Vicente-Vicente L, Ferreira L, Gonzalez-Buitrago JM, Lopez-Hernandez FJ, Lopez-Novoa JM, Morales AI. Increased urinary excretion of albumin, hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats. Toxicology. 2013;304(304):83–91. doi:10.1016/j.tox.2012.12.00623261757
   PubMed Web of Science ®Google Scholar
• Zhou Y, Vaidya VS, Brown RP, et al. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci. 2008;101(1):159–170. doi:10.1093/toxsci/kfm26017934191
   PubMed Web of Science ®Google Scholar
• Gautier J-C, Zhou X, Yang Y, et al. Evaluation of novel biomarkers of nephrotoxicity in Cynomolgus monkeys treated with gentamicin. Toxicol Appl Pharmacol. 2016;303(303):1–10. doi:10.1016/j.taap.2016.04.01227105553
   PubMed Web of Science ®Google Scholar
• Zhou X, Ma B, Lin Z, et al. Evaluation of the usefulness of novel biomarkers for drug-induced acute kidney injury in beagle dogs. Toxicol Appl Pharmacol. 2014;280(1):30–35. doi:10.1016/j.taap.2014.07.00225034533
   PubMed Web of Science ®Google Scholar
• Com E, Boitier E, Marchandeau J-P, et al. Integrated transcriptomic and proteomic evaluation of gentamicin nephrotoxicity in rats. Toxicol Appl Pharmacol. 2012;258(1):124–133. doi:10.1016/j.taap.2011.10.01522061828
   PubMed Web of Science ®Google Scholar
• Meistermann H, Norris JL, Aerni H-R, et al. Biomarker discovery by imaging mass spectrometry: transthyretin is a biomarker for gentamicin-induced nephrotoxicity in rat. Mol Cell Proteomics. 2006;5(10):1876–1886. doi:10.1074/mcp.M500399-MCP20016705188
   PubMed Web of Science ®Google Scholar
• Bellei E, Cuoghi A, Monari E, et al. Proteomic analysis of urine in medication-overuse headache patients: possible relation with renal damages. J Headache Pain. 2012;13(1):45–52. doi:10.1007/s10194-011-0390-921997203
   PubMed Web of Science ®Google Scholar
• Bellei E, Monari E, Cuoghi A, et al. Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache. J Headache Pain. 2013;14(1):6. doi:10.1186/1129-2377-14-623565828
   PubMed Web of Science ®Google Scholar
• Kuypers DRJ, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit. 2010;32(4):394–404. doi:10.1097/FTD.0b013e3181e0681820526235
   PubMed Web of Science ®Google Scholar
• Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant. 2007;22(7):1963–1968. doi:10.1093/ndt/gfm13317395652
   PubMed Web of Science ®Google Scholar
• Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol. 2005;16(5):1501–1511. doi:10.1681/ASN.200410088215772250
   PubMed Web of Science ®Google Scholar
• Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF. Calcineurin Inhibitor–Induced Nephrotoxicity and Renal Expression of P-glycoprotein. Pharmacotherapy. 2005;25(6):779–789. doi:10.1592/phco.2005.25.6.77915927895
   PubMed Web of Science ®Google Scholar
• Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DRJ. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol. 2009;20(11):2468–2480. doi:10.1681/ASN.200902019219762492
   PubMed Web of Science ®Google Scholar
• Moore J, McKnight AJ, Dohler B, et al. Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure. J Am Soc Nephrol. 2012;23(11):1891–1899. doi:10.1681/ASN.201203026023064017
   PubMed Web of Science ®Google Scholar
• Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86(4):396–402. doi:10.1038/clpt.2009.13919625999
   PubMed Web of Science ®Google Scholar
• Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol. 2010;80(11):1762–1767. doi:10.1016/j.bcp.2010.08.01920813096
   PubMed Web of Science ®Google Scholar
• Wen X, Buckley B, McCandlish E, et al. Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am J Pathol. 2014;184(5):1299–1308. doi:10.1016/j.ajpath.2014.01.02524641901
   PubMed Web of Science ®Google Scholar
• Iwata K, Aizawa K, Kamitsu S, et al. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol. 2012;16(6):843–851. doi:10.1007/s10157-012-0638-y22569819
   PubMed Web of Science ®Google Scholar
• Chang C, Hu Y, Hogan SL, et al. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Int J Mol Sci. 2017;18(7):7. doi:10.3390/ijms18071333
   Web of Science ®Google Scholar
• Izzedine H, Hulot J-S, Villard E, et al. Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy. J Infect Dis. 2006;194(11):1481–1491. doi:10.1086/50854617083032
   PubMed Web of Science ®Google Scholar
• Rodríguez‐Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48(11):e108–16. doi:10.1086/59850719400747
   PubMed Web of Science ®Google Scholar
• Wanga V, Venuto C, Morse GD, et al. Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics. 2015;25(9):450–461. doi:10.1097/FPC.000000000000015626148204
   PubMed Web of Science ®Google Scholar
• E, Zubowska M, Misiura K. Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. J Pediatr Hematol Oncol. 2005;27(11):582–589. doi:10.1097/01.mph.0000187429.52616.8a16282887
   PubMedGoogle Scholar
• Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011;55(12):5475–5479. doi:10.1128/AAC.00168-1121947388
   PubMed Web of Science ®Google Scholar
• Van Driest SL, McGregor TL, Velez Edwards DR, et al. Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy. PLoS One. 2015;10(6):e0127791.26030142
   PubMed Web of Science ®Google Scholar
• Yao J, Huang T, Fang X, et al. Disruption of gap junctions attenuates aminoglycoside-elicited renal tubular cell injury. Br J Pharmacol. 2010;160(8):2055–2068. doi:10.1111/j.1476-5381.2010.00860.x20649601
   PubMed Web of Science ®Google Scholar
• Eadon MT, Wheeler HE, Stark AL, et al. Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet. 2013;22(19):4007–4020. doi:10.1093/hmg/ddt24023720496
   PubMed Web of Science ®Google Scholar
• Albano LMJ, Sakae PPO, Mataloun MMGB, Leone CR, Bertola DR, Kim CA. Hydronephrosis in Schinzel-Giedion syndrome: an important clue for the diagnosis. Rev Hosp Clin Fac Med Sao Paulo. 2004;59(2):89–92. doi:10.1590/S0041-8781200400020000815122424
   PubMedGoogle Scholar
• Price PM, Safirstein RL, Megyesi J. The cell cycle and acute kidney injury. Kidney Int. 2009;76(6):604–613. doi:10.1038/ki.2009.22419536080
   PubMed Web of Science ®Google Scholar
• Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 2010;10(1):54–61. doi:10.1038/tpj.2009.4519786980
   PubMed Web of Science ®Google Scholar
• Goekkurt E, Al-Batran S-E, Hartmann JT, et al. Pharmacogenetic analyses of a Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol. 2009;27(17):2863–2873. doi:10.1200/JCO.2008.19.171819332728
   PubMed Web of Science ®Google Scholar
• Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P. Differential gene expression following early renal ischemia/reperfusion. Kidney Int. 2003;63(5):1714–1724. doi:10.1046/j.1523-1755.2003.00928.x12675847
   PubMed Web of Science ®Google Scholar
• Grigoryev DN, Liu M, Hassoun HT, Cheadle C, Barnes KC, Rabb H. The local and systemic inflammatory transcriptome after acute kidney injury. J Am Soc Nephrol. 2008;19(3):547–558. doi:10.1681/ASN.200704046918235097
   PubMed Web of Science ®Google Scholar
• Amin RP, Vickers AE, Sistare F, et al. Identification of putative gene based markers of renal toxicity. Environ Health Perspect. 2004;112(4):465–479. doi:10.1289/ehp.668315033597
   PubMed Web of Science ®Google Scholar
• Dadarkar SS, Fonseca LC, Mishra PB, et al. Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood. J Appl Toxicol. 2011;31(2):117–130.20623750
   PubMed Web of Science ®Google Scholar
• Davis JW, Goodsaid FM, Bral CM, et al. Quantitative gene expression analysis in a nonhuman primate model of antibiotic-induced nephrotoxicity. Toxicol Appl Pharmacol. 2004;200(1):16–26. doi:10.1016/j.taap.2004.02.00115451304
   PubMed Web of Science ®Google Scholar
• Hung Y-C, Huang GS, Lin L-W, Hong M-Y, Se P-S. Thea sinensis melanin prevents cisplatin-induced nephrotoxicity in mice. Food Chem Toxicol. 2007;45(7):1123–1130. doi:10.1016/j.fct.2006.12.01717303299
   PubMed Web of Science ®Google Scholar
• Aguado-Fraile E, Ramos E, Conde E, et al. A Pilot Study Identifying a Set of microRNAs As Precise Diagnostic Biomarkers of Acute Kidney Injury. PLoS One. 2015;10(6):e0127175. doi:10.1371/journal.pone.012717526079930
   PubMed Web of Science ®Google Scholar
• Gutierrez-Escolano A, Santacruz-Vazquez E, Gomez-Perez F. Dysregulated microRNAs involved in contrast-induced acute kidney injury in rat and human. Ren Fail. 2015;37(9):1498–1506. doi:10.3109/0886022X.2015.107732226337190
   PubMed Web of Science ®Google Scholar
• Kanki M, Moriguchi A, Sasaki D, et al. Identification of urinary miRNA biomarkers for detecting cisplatin-induced proximal tubular injury in rats. Toxicology. 2014;324(324):158–168. doi:10.1016/j.tox.2014.05.00424863737
   PubMed Web of Science ®Google Scholar
• Lee CG, Kim JG, Kim HJ, et al. Discovery of an integrative network of microRNAs and transcriptomics changes for acute kidney injury. Kidney Int. 2014;86(5):943–953. doi:10.1038/ki.2014.11724759152
   PubMed Web of Science ®Google Scholar
• Pavkovic M, Riefke B, Ellinger-Ziegelbauer H. Urinary microRNA profiling for identification of biomarkers after cisplatin-induced kidney injury. Toxicology. 2014;324(324):147–157. doi:10.1016/j.tox.2014.05.00524880025
   PubMed Web of Science ®Google Scholar
• Pavkovic M, Robinson-Cohen C, Chua AS, et al. Detection of Drug-Induced Acute Kidney Injury in Humans Using Urinary KIM-1, miR-21, −200c, and −423. Toxicological Sciences. 2016;152(1):205–213. doi:10.1093/toxsci/kfw07727122240
   PubMed Web of Science ®Google Scholar
• Saikumar J, Hoffmann D, Kim T-M, et al. Expression, circulation, and excretion profile of microRNA-21, −155, and −18a following acute kidney injury. Toxicol Sci. 2012;129(2):256–267. doi:10.1093/toxsci/kfs21022705808
   PubMed Web of Science ®Google Scholar
• Sun S, Zhang T, Ding D, et al. Circulating microRNA-188, −30a, and −30e a early biomarkers for contrast-induced acute kidney injury. J Am Heart Assoc. 2016;116:1–11.
   Google Scholar
• Wolenski FS, Shah P, Sano T, et al. Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage. J Appl Toxicol. 2016;11.
   Web of Science ®Google Scholar
• Zhou XB, Qu Z, Zhu C, et al. Identification of urinary microRNA biomarkers for detection of gentamicin-induced acute kidney injury in rats. Regulatory Toxicology Pharmacology. 2016;78:78–84. doi:10.1016/j.yrtph.2016.04.00127074385
   PubMed Web of Science ®Google Scholar
• Oliveira JF, Silva CA, Barbieri CD, Oliveira GM, Zanetta DM, Burdmann EA. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009;53(7):2887–2891.19364846
   PubMed Web of Science ®Google Scholar
• Qiu Y, Hong M, Li H, et al. Time-series pattern of gene expression profile in gentamycin-induced nephrotoxicity. Toxicol Mech Methods. 2014;24(2):142–150. doi:10.3109/15376516.2013.86978024274596
   PubMed Web of Science ®Google Scholar
• Eadon MT, Hack BK, Alexander JJ, Xu C, Dolan ME, Cunningham PN. Cell cycle arrest in a model of colistin nephrotoxicity. Physiol Genomics. 2013;45(19):877–888. doi:10.1152/physiolgenomics.00076.201323922129
   PubMed Web of Science ®Google Scholar
• Uehara T, Horinouchi A, Morikawa Y, et al. Identification of metabolomic biomarkers for drug-induced acute kidney injury in rats. J Appl Toxicol. 2014;34(10):1087–1095.24114878
   PubMed Web of Science ®Google Scholar
• Boudonck KJ, Mitchell MW, Nemet L, et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol. 2009;37(3):280–292.19380839
   PubMed Web of Science ®Google Scholar
• Zhang P, Chen J, Wang Y, et al. Discovery of Potential Biomarkers with Dose- and Time-Dependence in Cisplatin-Induced Nephrotoxicity Using Metabolomics Integrated with a Principal Component-Based Area Calculation Strategy. Chem Res Toxicol. 2016;29(5):776–783.27030963
   PubMed Web of Science ®Google Scholar
• Hanna MH, Segar JL, Teesch LM, Kasper DC, Schaefer FS, Brophy PD. Urinary metabolomic markers of aminoglycoside nephrotoxicity in newborn rats. Pediatr Res. 2013;73(5):585–591.23411940
   PubMed Web of Science ®Google Scholar
• Andreoli SP. Acute renal failure in the newborn. Semin Perinatol. 2004;28(2):112–123.15200250
   PubMed Web of Science ®Google Scholar
• Marquez MG, Cabrera I, Serrano DJ, Sterin-Speziale N. Cell proliferation and morphometric changes in the rat kidney during postnatal development. Anat Embryol (Berl). 2002;205(5–6):431–440.12382146
   PubMedGoogle Scholar
• Mattes WB, Kamp HG, Fabian E, et al. Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling. Biomed Res Int. 2013;2013:202497.23762827
   PubMed Web of Science ®Google Scholar
• Thukral SK, Nordone PJ, Hu R, et al. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol Pathol. 2005;33(3):343–355.15805072
   PubMed Web of Science ®Google Scholar